Skip to main content

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor conferences:

  • Cowen’s Virtual 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022. Fireside chat at 9:00 a.m. ET.
  • Jefferies Global Healthcare Conference at the New York Marriot Marquis on Wednesday, June 8, 2022. Presentation at 1:30 p.m. ET.

A live webcast of the Cowen fireside chat and Jefferies presentation will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is currently in development for ocular cancers, with an ongoing Phase 2 dose escalation clinical trial evaluating first-line treatment of choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, leveraging Aura’s technology platform, Aura is developing AU-011 more broadly across multiple cancers, starting with a planned Phase 1 clinical trial in patients with non-muscle invasive bladder cancer. Aura is headquartered in Cambridge, MA.

For more information, visit aurabiosciences.com, or follow us on Twitter and LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  217.57
-4.46 (-2.01%)
AAPL  260.89
-1.88 (-0.72%)
AMD  231.98
-6.05 (-2.54%)
BAC  50.80
-0.73 (-1.41%)
GOOG  253.97
+2.63 (1.05%)
META  733.70
+0.43 (0.06%)
MSFT  523.88
+6.22 (1.20%)
NVDA  180.47
-0.69 (-0.38%)
ORCL  271.95
-3.20 (-1.16%)
TSLA  435.19
-7.41 (-1.67%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.